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Feeney et al. (2018) make a valid argument for restrictions on the exclusivity of foundational
technologies such as CRISPR. The issue of balancing intellectual property right with access to
scientific and technological advancements is certainly not new. In our commentary, we argue that
the human right to science offers a more concrete basis for governments to balance their competing
commitments in promoting scientific development on the one hand, and ensuring benefit-sharing
on the other, in ways that advance social justice under non-ideal conditions.
The Human Right to Science
The human right to science is recognized by Article 27 of the Universal Declaration of Human
Rights (“Universal Declaration”) and Article 15 of the International Covenant on Economic, Social
and Cultural Rights (“Covenant”). The Covenant binds States Parties (i.e., states that have ratified
it), whereas the Universal Declaration binds all states since it has achieved customary international
law status. As a result, states must “respect, protect, promote, and fulfill” the right to science. To
do so, states must refrain from violating or interfering with the enjoyment of a right (respect), take
active measures to prevent violation of the right (protect) and to advocate for, encourage, and
otherwise support the advancement of the right (promote), and, implement the affirmative
measures that are necessary to fully realize the right (fulfill) (Leckie, Gallagher, and Gallagher,
20). To discharge these obligations, state actions must be deliberate, concrete, and as targeted as
possible (Committee on Economic. Social and Cultural Rights 1991).
At its core, the human right to science encompasses two distinct but interrelated sets of rights: the
right of everyone to benefit from advancements in science and technology and the right to freedom
of scientific research (Boggio and Romano 2018). Also, Article 15.2 of the Covenant demands
that States Parties take steps “to achieve the full realization of this right … [including] those
necessary for the conservation, the development and the diffusion of science and culture.” Human
rights law triggers people’s right “to have a legislative and policy framework adopted and
implemented which aims at making the benefits of scientific progress available and accessible —
both through encouraging new scientific discoveries and through removing barriers for existing
scientific knowledge to be used for public benefit” (London, Cox, and Coomans 2016).
Right to Science as Policy Justification to (Re-)Calibrate Patent Exclusivity
The issue of patent protection for foundational technologies implicates primarily the right of
everyone to benefit from scientific and technological advancements as codified in Article 15.1.b
of the Covenant. This provision speaks to the right to access scientific knowledge, the material
results of scientific research and the means to access knowledge and results. As Feeney et al.
(2018) explain, overly robust patent protection for foundational technologies may, in fact, limit
access to the material benefits of the advancements in science and technology at multiple levels

and could even stifle scientific progress altogether. In response, they propose a ‘non-ideal solution’
that is primarily directed at limiting the exclusionary rights of the patentee. In implementation,
they argue that limitations should be imposed on certain technical fields (e.g., environment or
health) in which patent rights are exercised, on certain types of activity that can be constrained by
such rights, and on the exclusivity period. We agree that the proposed response is an important
one to consider not only for the reasons that the authors have provided but also because human
rights analysis will similarly highlight the obligation of governments to ensure that patent rights
do not compromise the capabilities of individuals to live well.
By human rights standards, governments must ensure that intellectual property rights do not
preclude access to the material benefits of scientific knowledge or research and development
(R&D). While this issue quickly turns into an empirical question—one that Feeney et al. (2018)
acknowledge to be an open one for the contested patent rights over CRISPR—what we want to
highlight in this commentary is that human rights law demands a shift in perspective. Intellectual
property regimes must be continuously refined, to ensure that everyone has the capability of
contributing to, as well as reap the benefits of, scientific innovation and technological
advancements.
To this end, intellectual property regimes must incorporate “flexibilities,” a term used by Farida
Shaheed, Special Rapporteur in the field of cultural rights, in her 2012 report (United Nations
2012). These “flexibilities” are needed to “[r]ecalibrat[e] intellectual property norms that may
present a barrier to the right to science and establish[…] greater coherence among them seem to
be necessary steps” to ensure that human rights standards are respected (United Nations 2012, 16).
It is important to note that “recalibrating” does not mean voiding or disregarding intellectual
property rights. Article 15.c of the Covenant provides that authors and inventors are entitled “to
benefit from the protection of the moral and material interests resulting from any scientific, literary
or artistic production.” Patents are part of this protection. However, the Covenant provides that
this protection is not absolute but must be balanced with the other human rights considerations
sanctioned by this instrument. The important difference between the right to science approach from
that proposed by Feeney et al. (2018) is the responsive dynamism that is implicit in calibrating
patent rights, as opposed to the more reactive imposition of limits entailed in the latter.
The Right to Science is action-oriented and advances a more participatory approach to
governance
While justifications for the restrictions proposed by Feeney et al. (2018) are well grounded in
social justice, it is less clear how these normative arguments can be translated into policy or
governance measures. The right to science, particularly where it is closely aligned with the more
established right to health, offers a more concrete basis for governments to balance their competing
commitments in promoting scientific development on the one hand and ensuring benefit-sharing
on the other. In addressing health inequalities, for instance, a human rights framework has been
developed to identify human rights instruments, as well as mechanisms, by which governments
can be held accountable under human rights law (Stronks et al. 2016).

Applying this human rights framework to R&D governance in health systems, accountability on
the part of governments could include proactively introducing policies that: adopt an inclusive
understanding of innovation to develop novel technologies for unmet needs through multiple
public- and private-sector partnerships; and promote innovative R&D models that delink research
funding from sales revenue. In addition, governmental responsibility would include monitoring
and assessing the overall effects of innovations on health systems for their intended and unintended
effects over time and if they help to reduce inequalities (Bigdeli, Peters, and Wagner 2014).
Importantly, the right to science is democratic and participatory in that it empowers individuals
through its prescription on everyone an equal opportunity to achieve health and wellness through
scientific R&D. Like the right to health, the right to science provides the basis for legal recourse,
which, if successful, can result in tangible changes in the intellectual property regime. We have
witnessed this in the context of access to innovative treatments for HIV/AIDS. Human rights
(relating to health and science) have mobilized people and supportive institutions to hold
governments accountable for addressing inequalities through social movements and market
transformation (Kapstein and Busby 2013).
In conclusion, we consider the right to science to complement the approach proposed by Feeney
et al. (2018). Patent regimes have been constructed for particular purposes, but without having to
completely overhaul what we have to ensure fairer outcomes, it must be supported by individual
empowerment, accountability mechanisms and social institutions that the right to science could
enable (Ho 2010).
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